Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp IGXT


Primary Symbol: T.IGX

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 'MONTPARK' Clinical Trial

GlobeNewswire 10 days ago

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

GlobeNewswire 13 days ago

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

GlobeNewswire March 21, 2024

IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 - Conference Call to Follow

GlobeNewswire March 14, 2024

IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

GlobeNewswire March 11, 2024

UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering

GlobeNewswire February 20, 2024

IntelGenx Launches Preferred Share Regulation A Offering

GlobeNewswire February 20, 2024

Studies Validate Advantages of Administering Drugs to Pets via IntelGenx's VetaFilm® Platform

GlobeNewswire February 5, 2024

IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®

GlobeNewswire December 18, 2023

IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000

GlobeNewswire December 5, 2023

IntelGenx Announces Changes to its Board of Directors

GlobeNewswire December 4, 2023

IntelGenx Announces Shareholder Approval of Financing Transactions

GlobeNewswire November 28, 2023

IntelGenx Receives Approval to Conduct 'MONTPARK' Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease

GlobeNewswire November 14, 2023

IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting

GlobeNewswire November 13, 2023

IntelGenx Reports Third Quarter 2023 Financial Results

GlobeNewswire November 9, 2023

IntelGenx and Tilray amend collaboration on VersaFilm products

Jocelyn Aspa November 6, 2023

IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray

GlobeNewswire November 6, 2023

IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 - Conference Call to Follow

GlobeNewswire November 2, 2023

IntelGenx Provides RIZAFILM® U.S. Commercialization Update

GlobeNewswire September 21, 2023

IntelGenx Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

GlobeNewswire September 19, 2023